Cell Therapy Manufacturing– tag –
-
Precision and Pace: Liv Hospital Details Step-by-Step Innovations in CAR-T Cell Manufacturing
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive, step-by-step guide to CAR-T cell manufacturing, spanning the entire process from leukapheresis to final formulation. The blueprint emphasizes stringent quality contr... -
Overcoming Raw Material Variability Challenges for Autologous Adoptive Cell Therapies: Risk-Based Control and Decentralized Manufacturing
PharmTech International Overview Raw material variability presents a significant challenge to product consistency and quality in autologous cell therapy manufacturing. A risk-based, phase-appropriate control strategy is crucial, identify... -
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
MD Anderson Researchers Identify Immature NK Cell Subpopulation in Donor Umbilical Cord Blood That Compromises CAR-NK Cell Therapy Antitumor Activity
Mirage News USA Overview Researchers at MD Anderson have discovered that a specific subpopulation of immature natural killer (NK) cells found in donor umbilical cord blood can diminish the antitumor activity of chimeric antigen receptor ... -
RoosterBio and Applied StemCell Partner to Scale iPSC-Based Bioprocess Solutions, Accelerating Cell Therapy Manufacturing
MD Tech Council (Facebook) USA Overview RoosterBio and Applied StemCell have formed a strategic partnership to scale iPSC-based bioprocess solutions, aiming to accelerate the commercial production of cell therapies. This collaboration in... -
Advancements in Cell and Gene Therapy Manufacturing: Automation, Cost Reduction, and Scalability Revolutionize Patient Access
Bioprocessing Summit Europe International Overview The cell and gene therapy (CGT) manufacturing sector faces significant operational challenges, including high costs and scalability constraints, particularly due to raw material variabil... -
Fate Therapeutics’ iPSC-Derived CAR-T FT819 Shows Safety and Improved Skin Scores in Refractory Systemic Sclerosis Phase 1; Repligen Acquires BioLife Solutions for $1.5 Billion
DeciBio USA Overview July 2026 highlights in next-generation therapeutics include Fate Therapeutics' preliminary Phase 1 data for FT819, an iPSC-derived CD19-targeted CAR-T cell therapy for treatment-refractory systemic sclerosis, demons... -
WuXi Advanced Therapies Significantly Expands Cell Therapy Manufacturing Capacity to Meet Surging Client Demand, Reinforcing GMP Capabilities and Process Development
WuXi Advanced Therapies China Overview WuXi Advanced Therapies announced a substantial expansion of its cell therapy manufacturing facilities. This significant investment aims to address the growing demand from clients for complex cell t... -
Hitachi Drives Industrialization of Cell Therapies with AI-Powered Manufacturing Innovation
Hitachi Japan Overview Hitachi has initiated a new collaboration with prominent research institutions to advance innovative cell processing technologies. This partnership is designed to significantly enhance the efficiency and scalabilit... -
BioPharma Dive Reports on Cell and Gene Therapy Manufacturing Frontlines: Viral Vector Supply Shortages and CDMO Market Soaring to $9.08 Billion by 2031
BioPharma Dive USA Overview BioPharma Dive analyzes key challenges and commercial opportunities in cell and gene therapy manufacturing, pinpointing viral vector production as the most severe supply constraint. Lonza is significantly expa...
